Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 5, 2000, Pages 673-676

  Chandrasekar, P H ^a   Cutright, Jessica ^a   Manavathu, Elias ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROBENZYLIDENEMALONONITRILE; AMPHOTERICIN B; ANTIFUNGAL AGENT; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG EFFICACY; GUINEA PIG; LUNG ASPERGILLOSIS; NONHUMAN; SURVIVAL;

EID: 0034016866     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.5.673     Document Type: Article

References (18)

1. Bodey, G., Bueltmann, B., Duguid, W., Gibbs, D., Hanak, H., Hotchi, M. et al. (1992). Fungal infections in cancer patients: an international survey. European Journal of Clinical Microbiology and Infectious Diseases 11, 99-109.
2. Denning, D. W. (1996). Therapeutic outcome in invasive aspergillosis. Clinical Infectious Diseases 23, 608-15.
3. Morrison, V. A., Haake, R. & Weisdorf, D. J. (1994). Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. American Journal of Medicine 96, 497-503.
4. Walsh, T. J. (1990). Invasive pulmonary aspergillosis in patients with neoplastic diseases. Seminars in Respiratory Infections 5, 111-22.
5. Denning, D. W., Lee, J. Y., Hostetler, J. S., Pappas, P., Kauffman, C. A., Dewsnup, D. H. et al. (1994). NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. American Journal of Medicine 97, 135-44.
6. Bowden, R., Chandrasekar, P. H., White, M., van Burik, J.-A. & Wingard, J. (1998). A double-blind, randomized, controlled trial of amphocil (ABCD) vs. amphotericin B (AmB) for treatment of invasive aspergillosis in immunocompromised patients. In Program and Abstracts of the Tenth International Symposium of Infections in the Immunocompromised Host Society, Davos, Switzerland, 1998.
7. Abraham, O. C., Manavathu, E. K., Cutright, J. L. & Chandrasekar, P. H. (1999). In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagnostic Microbiology and Infectious Disease 33, 7-11.
8. Espinel-Ingroff, A. (1998). In vitro activity of the new triazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. Journal of Clinical Microbiology 36, 198-202.
9. Barry, A. L. & Brown, S. D. (1996). In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrobial Agents and Chemotherapy 49, 1948-9.
10. Radford, S. A., Johnson, E. M. & Warnock, D. W. (1997). In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent against emerging and less common mold pathogens. Antimicrobial Agents and Chemotherapy 41, 841-3.
11. Manavathu, E. K., Cutright, J. L. & Chandrasekar, P. H. (1998). Organism-dependent fungicidal activity of azoles. Antimicrobial Agents and Chemotherapy 42, 3018-21.
12. Jezequel, S. G., Clark, M., Cole, S., Evans, K. E. & Wastall, P. (1995). UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pre-clinical pharmacokinetics. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995, Abstract F 76, p. 126. American Society for Microbiology, Washington, DC.
13. Manavathu, E. K., Alangaden, G. J. & Lerner, S. A. (1996). A comparative study of the broth micro-and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus. Canadian Journal of Microbiology 42, 960-4.
14. Weisbroth, S. H. & Fudens, J. H. (1972). Use of ketamine hydrochloride as an anaesthetic in laboratory rabbits, rats, mice and guinea pigs. Laboratory Animal Science 22, 904-6.
15. Murphy, M., Bernard, E. M., Ishimaru, T. & Armstrong, D. (1997). Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy 41, 696-8.
16. George, D., Miniter, P. & Andriole, V. T. (1996). Efficacy of UK-109,496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy 40, 86-91.
17. Martin, M. V., Yates, J. & Hitchcock, C. A. (1997). Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrobial Agents and Chemotherapy 41, 13-6.
18. Patterson, T. F., Kirkpatrick, W. R. & McAtee, R. K. (1997). The efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. In Program and Abstracts of the Thirty-Seventh Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract B14, p. 29. American Society for Microbiology, Washington, DC.